Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JPM 2026
Biotech
With 200 JPM meetings, Novo BD head seeks out the next Metsera
Tamara Darsow framed Novo's bid for Metsera as a declaration that “we were serious about getting the right innovation into our pipeline.”
Angus Liu
Jan 27, 2026 5:25pm
Inside Beam's 'big push' for in vivo gene editing
Jan 21, 2026 7:52am
Why Nkarta's CEO wore head-to-toe pink at JPM—and why it matters
Jan 20, 2026 4:25pm
Fierce Pharma
Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO
Jan 16, 2026 1:00pm
JPM26: Chugai chases new science and name recognition
Jan 16, 2026 5:28am
Fierce Pharma
Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears
Jan 15, 2026 10:42am
